3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street

When the curtain closed on 2022, the ageless Dow Jones Industrial Average, widely followed S&P 500, and growth-dependent Nasdaq Composite, respectively finished lower by

9%, 19%, and 33%. It was, collectively, the worst performance for Wall Street in 14 years. But don't think for a moment that a down year for equities did anything to dent

Wall Street's optimism. Even though down years are an inevitable part of the investing cycle, analysts are well aware that the three major U.S. stock indexes head higher over the

long term. This is why most analyst price targets point to upside in equities. But there's a big difference between expecting a stock to gain 20%, 30%, or maybe 50% over

the next 12 months, and believing it'll skyrocket 600% or 700% over the next year. What follows are three under-the-radar small-cap stocks that select Wall Street analysts believe

offer between 590% and 772% upside in 2023. Ocugen: Implied upside of 590% The first lesser-known stock with to-the-moon potential in 2023, at least according to one Wall

Street analyst, is clinical-stage biotech stock Ocugen (NASDAQ: OCGN). Analyst Jonathan Aschoff of Roth Capital foresees shares of Ocugen reaching $8, which, if accurate, would

represent 590% upside from where the stock closed on January 19.  As the company's name alludes, its primary focus is researching and developing ocular therapies. However,

it's Ocugen's foray into the COVID-19 vaccine arena that's raised eyebrows over the past couple of years.